.png){kind=icon}
.png){kind=icon}
Return
N6-methyladenosine (m6A) RNA methylation: a potential clinical therapeutic target in cardiocerebrovascular diseases
.png){kind=icon}
PRE
AI
H
Y
R
X
X
DOI：10.1016/j.pharmthera.2025.108972.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Cardiocerebrovascular disease (CCD) is a condition related to the heart and blood vessels affecting the cardiovascular system. The disease is caused by various pathogenic factors that damage the heart and brain tissues. CCD significantly threatens human health due to the increased incidence, disability, and mortality, but effective treatment options remain lacking. As precision medicine has taken center stage in recent years, the relationship between epigenetics and CCD has been increasingly studied. N6-methyladenosine (m6A) represents a dynamic and reversible methylation occurring on the sixth nitrogen atom of RNA adenine. This modification is essential in epigenetic regulation, involving the coordinated methyltransferase action, methylated reading proteins, and demethylases. Being a prevalent internal modification in eukaryotic messenger ribonucleic acid (mRNA), m6A is indispensable in numerous bioprocesses. m6A modification has been found to govern gene expression at the epigenetic, transcriptional, and post-transcriptional levels. This alteration can affect tumor development, regulate spermatogenesis and hematopoietic stem cell differentiation, thereby serving as a biomarker for CCD diagnosis and prognosis. Accordingly, we reviewed the function, mechanism, and value of m6A modification in CCD to present a fresh perspective for early diagnosis and clinical treatment.
Journal
P
IF:
12.5
Papers:
4.5K
Citations:
2.6W
Organization
Cited Papers